A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific protein. This is the first application of the new technology, called DNA-encoded monoclonal antibody (DMAb), for cancer immunotherapy. The study was published online in Cancer Immunology, Immunotherapy.
Prostate cancer is the second most common cancer in men worldwide. Traditional treatments are invasive and can impair the quality of life of patients, underscoring the need for alternative therapeutic strategies, including immunotherapy. One of the immunotherapeutic approaches that has been explored thus far relies on the use of monoclonal antibodies that specifically target a protein present on the surface of prostate cancer cells called prostate specific membrane antigen (PSMA) to elicit an anti-tumor immune response and control the cancer. Although promising, this strategy is limited by the production cost required to make these therapeutic antibodies. Additionally, multiple infusions are often required to achieve efficacy.
Wistar researchers devised a novel DNA-based approach in which an engineered DNA plasmid is constructed and used to deliver the instructions to make the desired anti-PSMA antibody so that the therapy can be generated in the patient’s body in a sustained manner. This research has important implications for the use of DNA-encoded monoclonal antibody technology as a platform for delivering the next generation of immunotherapies for cancer and many human diseases.
“This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivoproduction of antibodies of major relevance to human cancer,” said David B. Weiner, Ph.D., executive vice president of The Wistar Institute, director of The Wistar Institute Vaccine & Immunotherapy Center, W.W. Smith Charitable Trust Professor in Cancer Research, and senior author of the study. “There is a great need for such new approaches for prostate disease as well as many other cancers. As recent data suggest, PSMA is an important cancer antigen expressed on many human prostate, bladder, renal as well as ovarian cancers, so additional study of the possible benefits of this therapy are important.”
The new technology was tested in mice for the ability to generate antibodies in their blood stream that would target human PSMA as well as target PSMA-positive tumors. Results showed that antibodies were able to bind to the cancer cells and recruited specific immune cells called natural killer cells, resulting in shrinkage of the tumor, significantly improving survival.
“Our data provide proof of concept that DMAb engineered DNA plasmids can be successfully used to target important cancers,” said Kar Muthumani, M.Sc., Ph.D., assistant professor in the Translational Tumor Immunology Program at Wistar, member of the Vaccine & Immunotherapy Center and lead author of the study. “The unique features of our synthetic DNA-based system make it a promising novel approach for cancer therapy, alone or in combination with other treatments.”
The Latest on: Synthetic DNA
- As a Wiser World Looks to Make a Strong Sustainable Recovery From COVID-19, Synthetic Biology to Receive New Opportunities for Growthon November 24, 2020 at 8:32 am
Stock quotes by finanzen.net New York, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Synthetic Biology Industry" - With humans continuing their ...
- Oligonucleotide Synthesis Markets, 2025 - Use of Synthesized Oligonucleotides in Molecular Diagnostics and Clinical Applications Driving Growth - Reseon November 24, 2020 at 8:21 am
The "Oligonucleotide Synthesis Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The oligonucleotide synthesis market is expected to ...
- Generating huge true random numbers using DNA synthesison November 24, 2020 at 1:45 am
Scientists have generated a huge true random number using DNA synthesis. It is the first time that a number of this magnitude has been created by biochemical means.
- BOC RNA and Dr. Shiyue Fang Announced Plans to Cooperate Closely in Sensitive DNA/RNA Synthesison November 23, 2020 at 12:14 am
Recently, BOC RNA and Shiyue Fang's team at Michigan Technological University reached a cooperative consensus to conduct sensitive DNA/RNA synthesis. DNA/RNA can coexist with many sensitive organic ...
- DNA synthesis method generates ‘true random numbers’on November 20, 2020 at 7:54 am
From slot machines to data encryption, many fields need true random numbers. Now researchers have generated them using DNA synthesis for the first time.
- DNA molecules yield biochemical random numberon November 20, 2020 at 7:05 am
ETH scientists have generated a huge true random number using DNA synthesis. It is the first time that a number of this magnitude has been created by biochemical means.
- Prolific Advancements in Biotechnology to Drive Global Synthetic Biology Market Trends Over 2019-2025on November 18, 2020 at 9:54 pm
This is attributable largely to broad application potential in synthetic genes, organisms and DNA components across the pharmaceutical product manufacturing and diagnostics sectors. Technological ...
- The DNA of life at its limitson November 18, 2020 at 5:05 pm
Genome streamlining has been predicted for organisms living in extreme environments where there are limited nutrients available for the synthesis of DNA. "And the plant epidermis is like cardboard." ...
- Twist Bioscience Continues Support for Next Generation of Synthetic Biologists Through Work with iGEM Competitionon November 16, 2020 at 5:05 am
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its continued ...
- Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNAon November 12, 2020 at 12:19 pm
Twist Bioscience Corporation (NASDAQ: TWST), Illumina, Inc. (NASDAQ: ILMN) and Western Digital (NASDAQ: WDC) today announced the formation of an alliance with Microsoft to advance the field of DNA ...
via Google News and Bing News